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Clinicopathologic Features Predictive of Distant
Metastasis in Patients Diagnosed With Invasive
Breast Cancer
Basim Ali, MD1; Fatima Mubarik, MBBS2; Nida Zahid, MB, BS, MSc3; and Abida K. Sattar, MD3
abstract
PURPOSE National Comprehensive Cancer Network and European Society for Medical Oncology guidelines
suggest screening for distant metastasis (M1) in symptomatic patients or those with locally advanced breast
cancer. These guidelines are based on studies that often used pathologic staging for analysis. Physician
variability in screening for M1 has also resulted in overuse of diagnostic tests. We sought to identify clinico-
pathologic features at diagnosis that could guide testing for metastatic disease.
METHODS Patients diagnosed with invasive breast cancer between January 2014 and December 2015 were
identified from our institutional database. Demographic and clinical variables were collected, including receptor
profiles and clinical TNM staging. Rates of upstaging for each clinical stage and rates of concordance of
pathologic and clinical staging were analyzed. Univariate analysis and multivariate regression analysis (P, .05)
identified predictors of upstaging to stage IV disease.
RESULTS A total of 370 patients met the inclusion criteria. Seventy patients (18.9%) had metastatic disease at
diagnosis. The rate of upstaging for stages I, IIA, IIB, and III were 0%, 5.6%, 18.8%, and 36.6%, respectively.
Advancing clinical stage, tumor size, and nodal status resulted in a significantly higher rate (P , .001) of
upstaging to M1 disease. Age and hormone receptor status were not associated with upstaging to stage IV
disease. Clinical stages I-III were concordant with pathologic staging in 65(42.8%) of 152 patients (kappa’s
index, 0.197; P , .000).
CONCLUSION Advancing clinical stage, tumor size, and nodal status at diagnosis were predictive of upstaging to
M1 disease in patients with breast cancer. Distant metastatic workup should be considered in patients with
clinical stage IIB disease or higher.
JCO Global Oncol 6:1346-1351. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Breast cancer is the most common malignancy af-
fecting women worldwide.1 The diagnosis of breast
cancer warrants accurate staging to make therapeutic
decisions and determine prognosis. However, recent
studies show that inappropriate screening tests have
contributed to increasing health care costs.2-4
The National Comprehensive Cancer Network and
European Society for Medical Oncology have issued
guidelines recommending staging imaging to rule out
distant metastasis only in symptomatic patients or in
those with locally advanced (stage III) breast cancer.5,6
Many of the studies used to inform these guidelines
have used pathologic staging for their analysis.7,8 Only
the clinical and not the pathologic stage is available to
the clinician at the time of initial presentation when the
decision for obtaining metastatic workup is made. The
pathologic stage after surgery can frequently be dis-
cordant with the clinical stage.9,10
Despite existing guidelines that discourage indis-
criminate and routine use of metastatic workup,
physician variability in obtaining such tests has been
reported.11,12 There is often overuse of diagnostic tests,
with unnecessary exposure to radiation and false-
positive results that warrant additional workup, lead-
ing to delays in care and a burden on the health system
with increasing health care costs. Conventional di-
agnostic tests for excluding metastasis include various
combinations of chest x-ray; liver, abdominal, or pelvic
ultrasound; bone scintigraphy; computed tomography
(CT) of the chest, abdomen, and pelvis; and more
recently, positron emission tomography (PET)–CT. The
additional cost of these tests may also be a deterrent to
seeking definitive care, thus resulting in delayed
presentation with advanced disease.13,14 The aim of
this study was to determine the clinicopathologic
features of invasive breast cancer that are predictive of
upstaging to stage IV and can aid physicians in their
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decisionmaking for obtainingmetastatic workup in patients
with clinical stage I-III disease.
METHODS
After obtaining approval from the Ethics Review Committee
of Aga Khan University in Karachi, Pakistan, a retrospective
review of a prospectively maintained institutional database
of patients diagnosed with breast cancer was performed. All
patients with invasive breast cancer diagnosed between
January 1, 2014, and December 31, 2015, were included.
Those with incomplete/irretrievable records, bilateral breast
cancer, a second primary cancer, ductal carcinoma in situ,
and recurrent and male breast cancer were excluded from
the analysis.
Clinical parameters collected included patient age, clinical
tumor size, and nodal status on physical examination and
breast imaging (mammogram and ultrasound). The final
clinical tumor size (cT) and clinical nodal status (cN) used
for correlation with upstaging was the largest/highest of the
estimated clinical tumor size (cT) and clinical burden of
nodal disease (cN), whether on physical examination or
breast imaging. At the time these patients were diagnosed,
it was not our institutional policy to routinely perform his-
tologic confirmation of axillary lymph nodes suggestive of
metastasis. Most, but not all, patients underwent biopsy
confirmation of axillary disease before undergoing surgery.
For consistency, we sought to use clinical suspicion alone
(based on examination and axillary imaging) to stage the
axilla.
At our institution, metastatic workup is routinely performed
in all patients with invasive breast cancer per patients’
requests (self-paying) or physician preference. The pre-
ferred imaging modalities to screen for distant metastasis
are bone scintigraphy and CT scan of the chest, abdomen,
and pelvis. However, to make the workup more affordable,
a chest x-ray, liver ultrasound scan, or CT scan of the chest
with liver cuts is often used. PET-CT was not available at our
institution during the study period. Information on the
imaging studies obtained for metastatic workup and their
respective findings (ie, presence or absence of metastasis)
was also recorded. Patients were determined to have stage
IV disease based on characteristic findings on metastatic
workup and/or multidisciplinary tumor board consensus. A
second imaging modality, such as magnetic resonance
imaging (MRI) and ultrasound, as appropriate, was used
when necessary to confirm distant metastasis.
The pathologic features included in the analysis for pre-
dicting upstaging included those that are available after
a core-needle biopsy, before definitive surgery (ie, histo-
logic grade using the Bloom-Richardson system and es-
trogen, progesterone, and human epidermal growth factor
receptor 2 [HER2] receptor status).
Patients identified as having metastatic disease (M1) on
staging workup obtained at diagnosis either did not have
surgery upfront or surgery at all. Although these patients
with M1 disease were used in the analysis for predicting
upstaging, they were excluded from the analysis of cor-
relating clinical and pathologic stages. Thus, the pathologic
tumor size (pT) and pathologic nodal status (pN) were
collected only for patients who had surgery upfront and
where the correlation of cT and cN with pT and pN, re-
spectively, could be meaningful. For the purpose of this
study, all TNM staging was performed and recorded
according to the 8th edition of the American Joint Com-
mittee on Cancer staging system.
Frequencies were calculated for categorical variables. The
rate of upstaging to stage IV disease was calculated for each
stage and was defined as the number of patients confirmed
to have distant metastasis on metastatic workup, divided by
the total number of patients tested. For each pathologic
stage, the rate of underestimation or overestimation of
clinical stage (discordance) was calculated and defined as
the number of patients with clinical stage lower or higher
than the final pathologic stage, divided by the total number
of patients within that pathologic stage.
Analysis was performed using χ2 test and Fisher’s exact
test, as appropriate. Cohen’s kappa was calculated when
comparing concordance of clinical and pathologic data. A
P value , .05 was considered significant. A univariate
CONTEXT
Key Objective
What are the clinicopathologic features that predict distant metastasis at diagnosis of breast cancer? Our study examined the
clinical and pathologic features available at the time of diagnosis that will allow physicians to evaluate the need for
metastatic workup, especially in a resource-limited setting.
Knowledge Generated
Only advancing tumor size and nodal status consistently predicted risk of distant metastasis at diagnosis in breast cancer.
Metastatic workup should be considered for patients with clinical stage IIB disease or higher.
Relevance
Our findings show that routine metastatic workup may be safely omitted in early-stage breast cancer.
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analysis followed by multivariate regression analysis (P ,
.05) was conducted for clinicopathologic features.
RESULTS
A total of 466 patients presented with invasive breast
cancer during the study period, of whom 370 met the
inclusion criteria. Median age at diagnosis was 51 years
(range, 18-95 years). Surgical pathology reports, for the
purpose of correlating clinical T and N with pathologic T
and N, were available for 152 (41%) of patients because
the remaining patients either had surgery after receiving
neoadjuvant systemic therapy or did not have surgery at all
(stage IV disease; Table 1).
Bone scans were performed in 336 (90.8%) of patients.
The second most commonly performed study was CT of
the chest with liver cuts, which was performed in 282
(76.2%) of patients. Other imaging techniques frequently
used at our institution to screen for distant metastasis in-
cluded chest x-ray (33.0%), CT of the abdomen and pelvis
(45.1%), and ultrasound of the liver (20.0%). Thirty-eight
(10.3%) of patients required an additional study, such as
MRI of the spine or thyroid ultrasound to evaluate le-
sions considered suggestive of metastasis on other imaging
studies.
A third of the patients (123 of 370) presented with locally
advanced, clinical stage III disease. Overall, 70 (18.9%) of
the patients were found to have distant metastasis on
metastatic workup. Bone (n = 42, 11.4%) was the most
frequently involved site, followed by lung (n = 30, 8.1%),
and liver (n = 22, 5.9%). Brain metastasis was found in 4
(1.1%) of patients.
The rate of upstaging to stage IV (M1) significantly corre-
lated with clinical anatomic stage (P, .001), clinical T size
(P, .001), clinical N (P, .001), and histologic grade (P =
.018; Table 2). Patients with clinical stages IIB (n = 19 of
101, 18.8%) and III (n = 45 of 123, 36.6%) were most
frequently upstaged to M1 after metastatic workup was
obtained (Fig 1). On multivariate analysis, the only clini-
copathologic features predictive of metastatic disease were
clinical T (P = .022) and N (P, .001) stage. Age, hormone,
or HER2 receptor status were not found to be significant
predictors of distant metastasis.
TABLE 1. Clinicopathologic Features of Breast Cancer in This Study
Cohort
Characteristic No. (%)
Clinical T size 370
cT1 62 (16.8)
cT2 180 (48.6)
cT3 53 (14.3)
cT4 75 (20.3)
Clinical N 365
cN0 159 (43.0)
cN1 174 (47.0)
cN2 27 (7.3)
cN3 5 (1.4)
Pathologic T size 319
pT1 28 (7.6)
pT2 91 (24.6)
pT3 31 (8.4)
pT4 2 (0.5)
ypT1-4 108 (27.2)
Surgery not performed (stage IV) 59 (18.0)
Pathologic N 332
pN0 96 (25.9)
pN1 51 (13.8)
pN2 11 (3.0)
pN3 7 (1.9)
ypN0-N3 108 (27.2)
Surgery not performed (stage IV) 59 (18.0)
Clinical anatomic stagea 370
I 39 (10.5)
IIA 107 (28.9)
IIB 101 (27.3)
III 123 (33.2)
Pathologic anatomic stage (upfront surgery)a 152
I 21 (5.7)
IIA 61 (16.5)
IIB 35 (9.5)
III 35 (9.5)
Histologic grade 348
I 13 (3.7)
II 147 (42.2)
III 188 (54.0)
Hormone receptor status 355
ER/PR positive, HER2 positive 37 (10.4)
ER/PR positive, HER2 negative 213 (60.0)
ER/PR negative, HER2 positive (HER2 enriched) 43 (18.1)
ER/PR negative, HER2 negative (triple negative) 62 (9.0)
(Continued in next column)
TABLE 1. Clinicopathologic Features of Breast Cancer in This Study
Cohort (Continued)
Characteristic No. (%)
Distant metastasis 370
M0 300 (81.1)
M1 70 (18.9)
Abbreviations: ER, estrogen receptor; HER2, human epidermal
growth factor receptor 2; PR, progesterone receptor.
aAccording to the 8th edition of the American Joint Committee on
Cancer staging system.
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Overall, clinical stages I through III were found to be
concordant with pathologic staging in fewer than half (n =
65 of 152, 42.8%) of the patients (kappa’s index 0.197;
P , .000). In patients in whom there was discordance
between clinical and pathologic stages (n = 87 of 152,
57.2%), the clinical stage was underestimated in 38.8%
(n = 59 of 152) and overestimated in 18.4% (n = 28 of 152)
of patients. The rates of underestimated clinical stage for
pathologic stages IIA, IIB, and III were as follows: stage IIA:
18.0% (n = 11 of 61); stage IIB: 60% (n = 21 of 35); and
stage III: 77.1% (n = 27 of 35; Fig 2)
DISCUSSION
The prevalence of distant metastasis in the absence of
clinical symptoms in patients with invasive breast cancer
is reported to be between 1.2% and 6.4%.3,8,15 This is
also reflected in national and international guidelines
recommending against routine use of metastatic workup
in patients with early-stage disease (stages I-IIB) or asymp-
tomatic patients.5,6 Many of the guidelines have been
based on studies that used pathologic staging to ana-
lyze rates of clinical upstaging to stage IV disease. Path-
ologic stage is frequently discordant with the clinical
stage, with studies reporting discordance in 32%-40% of
patients.9,10
Our study is unique for several reasons. To our knowledge,
this is the first study to report upstaging rates for each
clinical stage in a Pakistani population. We also attempted
to identify clinicopathologic features available at the time of
diagnosis to predict upstaging to stage IV disease and thus
inform subsequent decisions for obtaining metastatic
workup. In addition, we divided stage II patients into stage
IIA and stage IIB to demonstrate a greater risk of distant
metastasis in the latter group. Finally, we correlated our
clinical and pathologic staging to estimate concordance
between both and to understand the impact of extrapo-
lating data from pathologic staging to guide decisions made
using clinical staging.
In a study of 412 patients, Puglisi et al7 found that 5.6% of
patients with stage II disease had bone metastasis at
presentation using pathologic staging. Another large study
of 2,612 patients demonstrated a 6% rate of upstaging in
patients with stage IIb disease using pathologic staging.16
Other studies have also noted a higher rate of upstaging in
patients with axillary disease and recommended that
metastatic workup should not be performed in a patient
with a clinically negative axilla.16,17
We propose several reasons for our overall higher rate of
upstaging. First, our analysis included all patients with in-
vasive breast cancer. This included those who were symp-
tomatic for metastatic disease, which may have contributed
to a higher rate of upstaging. Second, a majority of our pa-
tients received a CT scan as part of their metastatic workup,
which is more sensitive than the staging modalities (chest
x-ray and ultrasound liver scan) used in some of the pre-
viously reported studies.
TABLE 2. Univariate Analysis of Clinicopathologic Features and Rates of Upstaging
After Metastatic Workup
Characteristic
No. (%)
PM0 Upstaged to M1
Clinical stage (N = 370) , .001
I 39 (100) 0 (0)
IIA 101 (94.4) 6 (5.6)
IIB 82 (81.2) 19 (18.8)
III 78 (63.4) 45 (36.6)
Clinical T size (N = 370) , .001
cT1 57 (91.9) 5 (8.1)
cT2 157 (87.2) 23 (12.8)
cT3 40 (75.5) 13 (24.5)
cT4 46 (61.3) 29 (38.7)
Clinical N size (n = 365) , .001
cN0 150 (94.3) 9 (5.7)
cN1 135 (77.6) 39 (22.4)
cN2 14 (51.9) 13 (48.1)
cN3 1 (20.0) 4 (80.0)
Histologic grade (n = 348) .017
I 13 (100) 0 (0)
II 114 (77.6) 33 (22.4)
III 159 (84.6) 29 (15.4)
Hormone receptor status (n = 355) .857
ER/PR positive, HER2 positive 32 (86.5) 5 (13.5)
ER/PR positive, HER2 negative 169 (79.3) 44 (20.7)
ER/PR negative, HER2 positive 35 (81.4) 8 (18.6)
ER/PR negative, HER2 negative 52 (83.9) 10 (16.1)
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor
receptor; PR, progesterone receptor.
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FIG 1. Patients with clinical stage IIB or III were most frequently
upstaged to M1 after metastatic workup was obtained.
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Finally, we were able to correlate clinical stage with patho-
logic stage in the subset of patients who received upfront
surgery (Fig 2). There was a trend toward underestimating
the clinical stage (cTN) at diagnosis when compared with
the pathologic stage (pTN) despite taking the largest value of
the three modalities (ie, clinical examination, mammogram,
and ultrasound) as the cT and cN. This underestima-
tion using clinical parameters appeared to be most pro-
nounced in patients with pathologic stage IIB, where 60%
were underestimated as having clinical stages I and IIA, and
in pathologic stage III, where 77% were clinically under-
estimated as having clinical stages I, IIA, or IIB. This may
partially explain our higher rates of upstaging to stage IV in
clinical stages IIB and III than that reported in the literature.
Boutros et al18 conducted a study of 2,059 patients and
developed a nomogram predictive of distant metastasis in
newly diagnosed patients with breast cancer. This nomo-
gramwas also validated using two other cohorts in the same
study. They reported tumor size and nodal status as the
only significant predictors of distant metastasis, which is
similar to our findings. Our study, as well as the one by
Boutros et al,18 showed that biologically aggressive variants
of breast cancer, such as grade III, HER2-enriched (or
triple-negative tumors) were not predictive of metastasis at
initial presentation.
It has been previously reported that treating physicians and
surgeons are reluctant to follow guidelines pertaining to
screening for distant metastasis.11,12,19 There is a greater
burden of advanced disease in our population compared
with studies reporting data from the US National Cancer
database.14 In this study, almost all patients were screened
for metastatic disease by imaging studies. In our experience,
this deviation from guidelines is at least partly due to the
desire of self-paying patients to obtain a full metastatic
workup, even in early disease.20 As demonstrated by
previous studies, our study also showed low rates of
upstaging to stage IV in clinical stages I (n = 0 of 40, 0%)
and stage IIA (n = 6 of 107, 5.6%).
Our results echo the importance of avoiding routine met-
astatic workup in these subsets of low-risk patients because
it leads to unnecessary cost, delay in treatment, and
anxiety, especially among those with false-positive results
who then require additional testing, such as an MRI or
ultrasound scan. It has been shown that appropriate ed-
ucational interventions can change surgeon attitudes and
practices toward metastatic screening.21 In addition, our
results also show approximately 50% concordance be-
tween clinical and pathologic stages, with a propensity
for the clinical underestimation of TNM staging. Thus,
some patients thought to have early-stage breast cancer
using all available clinical data, such as examination and
breast imaging, may actually have more advanced dis-
ease on pathologic examination. Because our upstaging
to M1 in early breast cancer, especially in stage IIB, is
high, obtaining metastatic workup in these patients may
be useful.
There are some limitations to our study. The retrospective
collection of data was challenging because of a lack of
standardized clinical documentation (no standardized elec-
tronic medical record) and thus variation in documentation
between breast consultants. This also prevented us from
differentiating between patients who presented with symp-
toms and those who were asymptomatic for metastatic
disease. Additionally, because of challenges with handling,
retrieving, and reviewing paper charts, we were only able
to include a small sample size of 370 patients.
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FIG 2. Pathologic stage in patients who received upfront surgery and the corresponding clinical TNM stages.
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In conclusion, our findings confirm guidelines that patients
with node-negative early-stage invasive breast cancer should
not routinely undergo a distant metastatic workup. Although
receptor status in the current era is an important determinant
of aggressiveness of disease, it should not be used to
determine the need for metastatic workup. We recommend
consideration for obtaining metastatic workup in patients
clinically determined to have stage IIB disease or higher. Our
findings also demonstrate a need for both patient and
provider education to avoid unnecessary testing.
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